Faropenem

Brands of Feropenem in Kenya

No Brands Available


Faropenem in Kenya : Brands,Price , Generics, Alternatives
Faropenem Chemical Structure

MODE OF ACTION

Faropenem is a new oral penem which shows broad antibacterial activity against both aerobic and anaerobic gram-positive and gram-negative bacteria. Faropenem is bactericidal, with a strong affinity for the high molecular penicillin-binding proteins (PBPs) of the cell wall, which is essential for the multiplication of bacilli; it, thus, acts by inhibiting the cell wall synthesis. Faropenem is highly stable against various beta-lactamases and binds preferentially to the PBPs, 2 and 1A,

INDICATIONS

Feropenem is indicated in the treatment of respiratory tract infections, urinary tract infections, skin and skin structure infections and gynecological infections.

DOSAGE AND ADMINISTRATION

Upper respiratory tract infections

150 mg – 200 mg t.i.d.

Lower respiratory tract infections

200 mg – 300 mg t.i.d.

ENT infections

200 mg – 300 mg t.i.d.

Genito-urinary infections

200 mg – 300 mg t.i.d.

Skin and skin structure infections

150 mg – 200 mg t.i.d.

Obstetric or Gynecological infections

150 mg – 200 mg t.i.d.

Duration of treatment: The dose/duration of treatment depends upon the severity of infection, clinical response, age of the patients, symptoms and bacteriological findings.

CONTRAINDICATIONS

Faropenem is contraindicated in patients with known hypersensitivity to any of the components of this product or to other drugs in the same class, or in patients who have demonstrated anaphylactic reactions to beta-lactams.

DRUG INTERACTIONS

Imipenem and cilastatin sodium combination: It has been reported that in animal studies (rat), the concentration of faropenem in the blood increases. It is due to the obstruction of metabolic fermentation by cilastatin.

Furosemide: It has been reported in animal studies , that the kidney toxicity of faropenem increases.

Sodium valproate: It has been reported that due to joint usage with carbapenem drugs (meropenem, panipenem and imipenem-cilastatin sodium), the concentration of valproic acid in the blood reduces, and there is a recurrence of epileptic fits.

ADVERSE EFFECTS

Shock (less than 0.1%), pseudo anaphylactic symptoms: it may cause a shock and symptoms of anaphylaxis, so observe carefully. In case of pain, oral abnormality or heaves, difficulty in breathing, dizziness, urge to excrete the bowels, tinnitus, generalized flushing, angioedema, perspiration, low blood pressure etc. Stop the medication and take appropriate steps.

Acute renal failure:

In case of acute renal failure etc., severe symptoms of dysfunction of kidney are observed, but when it becomes abnormal, stop the medication and take appropriate measures.
Severe colitis accompanied with bloody stool of pseudomembranal colitis: Patient has to be under careful examination as severe colitis may appear, along with bloody stool due to pseudomembranal colitis etc. If the stomachache and diarrhea persist, stop the medication immediately and take appropriate measures.

Mucocutaneous-ocular syndrome (Stevens Johnson syndrome):

Please observe carefully as mucocutaneous-ocular syndrome (Stevens Johnson syndrome), toxic epidermal necrosis (Lyell syndrome) and Stevens-Johnson syndrome may appear, therefore when such symptoms are indicated, stop the medication immediately and take appropriate measures like administering the medicine for adrenal cortex hormone, etc.

Interstitial Pneumonia:

in case of symptoms such as pyrexia, cough, breathing problems, abnormalities in the chest x-ray are revealed along with interstitial pneumonia, stop the medication immediately and take appropriate measures like administering the medicine for adrenal cortex hormone etc.
Liver function disorder, Jaundice: Observe closely by taking periodic tests etc. because rise in the levels of AST (SGOT), ALT (SGPT), ALP etc., will be indicated along with jaundice, hence in case of abnormality, stop administering the medication and take appropriate steps.

Agranulocytosis:

There can be risk of agranulocytosis so be cautious. In case of abnormality, stop the medication and take steps as appropriate.
Striated muscle softening, Rhabdomyolysis: Rhabdomyolysis has the symptoms of muscular pain, lethargy, increase in CK (CPK), rising level of myoglobin in blood and urine can occur, which can lead to severe kidney dysfunction like renal failure. When these kind of symptoms appear stop the medication and take appropriate steps.

Pulmonary infiltrates with eosinophilia (PIE) syndrome:

The possibility of PIE syndrome has been reported along with the increase in acidocytes in case of symptoms such as pyrexia, cough, breathing problems, abnormality in the chest x-ray, stop the medication immediately and take appropriate measures like administering the medicine for adrenal cortical hormone, etc.

Hypersensitivity reactions:

rash, pyrexia, redness, hives, red spots on the skin, etc.
Abnormal laboratory findings: increase in liver function tests (ALT, AST, bilirubin, LDH, etc.), eosinophilia, increase in BUN, Creatinine, changes in granulocyte and platelets.

Vitamin deficiency:

Symptoms of vitamin K deficiency (low prothrombin, tendency of hemorrhage, etc). symptoms of vitamin B-group deficiency (inflammation of the tongue, stomatitis, lack of appetite, neuritis, etc.) might occur rarely.

Gastrointestinal disorders:

Vomiting, stomachache, diarrhea, lack of appetite, gastritis, constipation, inflammation of the corners of the mouth and lips, stomatitis.

Others:

Burning sensation, headache, dizziness, drowsiness, edema, dryness of the mouth and lips, change in nail color, and washed-out feeling occurs rarely.

Reporting of suspected adverse reactions:

The PPB Department of Pharmacovigilance was set up with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting, and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Reporting suspected adverse reactions after authorization of the medicinal product are important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals/ Patients are encouraged to report any suspected adverse reactions via Pharmacovigilance Yellow Form, pv@pharmacyboardkenya.org or clicking below button:


Faropenem in Kenya
Faropenem in Kenya
Faropenem in Kenya
Faropenem in Kenya
Faropenem in Kenya
Faropenem in Kenya

Clinical | Pharmacokinetic data


Pregnancy Category: N (Not classified yet
Routes of Administration: Oral
Bioavailability: 70%–80%
Protein Binding: 91-95%
Metabolosim: Not Available
Onset of Action: Not Available
Elimination Half life: 1 hour
Excretion: Renal

Legal Status | Dosage forms & Strengths


Prescription Category:
Prescription only Medicine (POM) , ℞-only
Narcotic Drugs and Psychotropic Substances (Control ) Act Schedule:
This drug is not a controlled substance under Narcotic Drugs and Psychotropic Substances (Control ) Act
Dosage Forms | Strengths:


Drug Indentifiers:

CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)


Drug Images

References/ Citation:




What was the patient being treated for
%d bloggers like this: